Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 5
1981 3
1982 8
1983 3
1984 10
1985 17
1986 18
1987 14
1988 11
1989 18
1990 13
1991 3
1992 15
1993 19
1994 9
1995 17
1996 15
1997 31
1998 28
1999 22
2000 47
2001 65
2002 82
2003 116
2004 125
2005 155
2006 180
2007 189
2008 175
2009 241
2010 231
2011 254
2012 332
2013 309
2014 322
2015 303
2016 253
2017 276
2018 239
2019 287
2020 270
2021 50
Text availability
Article attribute
Article type
Publication date

Search Results

4,282 results
Results by year
Filters applied: . Clear all
Page 1
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A. DiNardo CD, et al. Blood. 2019 Jan 3;133(1):7-17. doi: 10.1182/blood-2018-08-868752. Epub 2018 Oct 25. Blood. 2019. PMID: 30361262 Free PMC article.
B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance. We report safety and efficacy of venetoclax with decitabine or azacitidine from a large, multicenter, phase 1b dose-escalation and expansion study. ...During dose esca …
B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML cells and treatment resistance. We report safety and efficacy of v …
Decitabine.
Hackanson B, Daskalakis M. Hackanson B, et al. Recent Results Cancer Res. 2014;201:269-97. doi: 10.1007/978-3-642-54490-3_18. Recent Results Cancer Res. 2014. PMID: 24756800 Review.
Several clinical trials showed promising activity of low-dose decitabine also in CML and hemoglobinopathies, whereas its efficacy in solid tumors is very limited. ...Recent and ongoing clinical trials investigate new dosing schedules, routes of administration, and combinat …
Several clinical trials showed promising activity of low-dose decitabine also in CML and hemoglobinopathies, whereas its efficacy in …
Effects of 5-Aza-2'-deoxycytidine (decitabine) on gene expression.
Seelan RS, Mukhopadhyay P, Pisano MM, Greene RM. Seelan RS, et al. Drug Metab Rev. 2018 May;50(2):193-207. doi: 10.1080/03602532.2018.1437446. Epub 2018 Feb 18. Drug Metab Rev. 2018. PMID: 29455551 Review.
5-Aza-2'-deoxycytidine (AzaD), also known as Decitabine, is a deoxycytidine analog that is typically used to activate methylated and silenced genes by promoter demethylation. ...
5-Aza-2'-deoxycytidine (AzaD), also known as Decitabine, is a deoxycytidine analog that is typically used to activate methylated and …
Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.
Bohl SR, Bullinger L, Rücker FG. Bohl SR, et al. Expert Rev Hematol. 2018 May;11(5):361-371. doi: 10.1080/17474086.2018.1453802. Epub 2018 Mar 27. Expert Rev Hematol. 2018. PMID: 29543073 Review.
Inducing differentiation and apoptosis of leukemic blasts by DNA-hypomethylating agents, like e.g. azacytidine (AZA) and decitabine (DAC), represent well-tolerated alternative treatment approaches. ...
Inducing differentiation and apoptosis of leukemic blasts by DNA-hypomethylating agents, like e.g. azacytidine (AZA) and decitabine ( …
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD, Pratz KW, Letai A, Jonas BA, Wei AH, Thirman M, Arellano M, Frattini MG, Kantarjian H, Popovic R, Chyla B, Xu T, Dunbar M, Agarwal SK, Humerickhouse R, Mabry M, Potluri J, Konopleva M, Pollyea DA. DiNardo CD, et al. Lancet Oncol. 2018 Feb;19(2):216-228. doi: 10.1016/S1470-2045(18)30010-X. Epub 2018 Jan 12. Lancet Oncol. 2018. PMID: 29339097 Clinical Trial.
Treatment with hypomethylating agents such as azacitidine and decitabine is common, but responses are modest and typically short-lived. ...The primary endpoints were the safety and pharmacokinetics of venetoclax plus decitabine or azacitidine, and to determine the m …
Treatment with hypomethylating agents such as azacitidine and decitabine is common, but responses are modest and typically short-live …
Decitabine.
Issa JP. Issa JP. Curr Opin Oncol. 2003 Nov;15(6):446-51. doi: 10.1097/00001622-200311000-00007. Curr Opin Oncol. 2003. PMID: 14624227 Review.
Two phase II trials have reported substantial clinical activity of decitabine in the myelodysplastic syndrome and in chronic myelogenous leukemia. ...Finally, ongoing efforts are deciphering the in vivo mechanisms of responses seen after decitabine administration. S …
Two phase II trials have reported substantial clinical activity of decitabine in the myelodysplastic syndrome and in chronic myelogen …
Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment.
Yu G, Wu Y, Wang W, Xu J, Lv X, Cao X, Wan T. Yu G, et al. Cell Mol Immunol. 2019 Apr;16(4):401-409. doi: 10.1038/s41423-018-0026-y. Epub 2018 Apr 5. Cell Mol Immunol. 2019. PMID: 29622799 Free PMC article.
A more significant inhibition of tumor growth and a prolongation of survival were observed in the CT26 mouse model after treatment with a combination of PD-1 blockade and decitabine than in mice treated with decitabine or PD-1 blockade alone. ...Therefore, decita
A more significant inhibition of tumor growth and a prolongation of survival were observed in the CT26 mouse model after treatment with a co …
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study.
Savona MR, Odenike O, Amrein PC, Steensma DP, DeZern AE, Michaelis LC, Faderl S, Harb W, Kantarjian H, Lowder J, Oganesian A, Azab M, Garcia-Manero G. Savona MR, et al. Lancet Haematol. 2019 Apr;6(4):e194-e203. doi: 10.1016/S2352-3026(19)30030-4. Lancet Haematol. 2019. PMID: 30926081 Clinical Trial.
In cycle 1, each patient received a cohort-defined dose of oral decitabine on day -3, a 1-h intravenous infusion of decitabine 20 mg/m(2) on day 1, and cohort-defined doses of oral decitabine plus cedazuridine on days 2-5. ...There was no evident increase in …
In cycle 1, each patient received a cohort-defined dose of oral decitabine on day -3, a 1-h intravenous infusion of decitabine
Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.
He PF, Zhou JD, Yao DM, Ma JC, Wen XM, Zhang ZH, Lian XY, Xu ZJ, Qian J, Lin J. He PF, et al. Oncotarget. 2017 Jun 20;8(25):41498-41507. doi: 10.18632/oncotarget.17241. Oncotarget. 2017. PMID: 28489568 Free PMC article. Review.
Although a number of clinical trials demonstrated benefits of decitabine treatment in elderly AML patients, the results remains controversial. ...Subgroup analyses of age, cytogenetics risk, AML type and bone marrow blast percentage showed no significant differences of tre …
Although a number of clinical trials demonstrated benefits of decitabine treatment in elderly AML patients, the results remains contr …
4,282 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page